已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Outcomes of Visceral Arterial Interposition Graft Reconstruction for Locally Advanced Pancreatic Cancer

医学 胰腺癌 外科 癌症 普通外科 内科学
作者
Jennifer A. Yonkus,Roberto Alva‐Ruiz,Jill J. Colglazier,Michael L. Kendrick,Manju Kalra,Todd E. Rasmussen,Randall DeMartino,Thomas C. Bower,Mark J. Truty,Bernardo C. Mendes
出处
期刊:Annals of Surgery [Ovid Technologies (Wolters Kluwer)]
标识
DOI:10.1097/sla.0000000000006350
摘要

Objective: The aim of this study is to determine perioperative outcomes and the patency of interposition conduits for visceral arterial reconstruction in this setting. Summary Background Data: Visceral arterial encasement in locally advanced pancreatic cancer was historically a contraindication for surgery. With modern effective neoadjuvant strategies, our recent experience has made advanced vascular resection and reconstruction feasible in selected patients. Methods: A retrospective review was performed of patients undergoing pancreatic tumor resection with en bloc arterial resection and interposition revascularization between 6/2002-10/2022. Endpoints included graft patency, vascular-related complications, reinterventions, morbidity, and mortality. Results: Visceral arterial reconstruction with interposition grafting was performed in 111 patients undergoing en bloc arterial resections for pancreatic cancer. Graft types included autologous arterial conduits (n=66, 58 superficial femoral artery (SFA) and 8 splenic artery), cryopreserved arterial allografts (n=24), autologous saphenous veins (n=12), synthetic conduits (n=8), and composite autologous artery and synthetic (n=1). Perioperative 90-day mortality decreased significantly over time to 5% in the last six years. Vascular complications related to arterial reconstruction occurred in 11% (n=12) and included pseudoaneurysm (n=6), graft thrombus (n=2), stenosis requiring reintervention (n=2), hepatic failure (n=1), and hepatic and intestinal ischemia (n=1). Nine (8%) patients underwent vascular-related reinterventions. After median follow-up of 17-months, primary patency was 81% for the entire cohort and was highest in the SFA group (95%). The donor limb/harvest site complication rate was 8% with 100% primary patency. Conclusion: Visceral arterial resection with interposition reconstruction for locally advanced pancreatic cancer can be performed with acceptable vascular morbidity and durable patency. Autologous SFA was the most suitable conduit for reconstructions in our experience, with highest primary patency.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
dldldldl完成签到 ,获得积分20
3秒前
T1aNer299发布了新的文献求助10
4秒前
小林同学0219完成签到 ,获得积分10
6秒前
LLL发布了新的文献求助10
6秒前
Carmen完成签到,获得积分10
12秒前
ANG完成签到 ,获得积分10
12秒前
16秒前
酒渡完成签到,获得积分10
16秒前
sandra发布了新的文献求助10
17秒前
nbing完成签到,获得积分10
21秒前
Esther应助dawn采纳,获得10
26秒前
30秒前
BW完成签到,获得积分10
31秒前
周冯雪完成签到 ,获得积分10
32秒前
CHERIE发布了新的文献求助10
35秒前
科研通AI2S应助T1aNer299采纳,获得10
35秒前
小二郎应助sandra采纳,获得10
36秒前
LXF关闭了LXF文献求助
40秒前
yuan发布了新的文献求助10
41秒前
41秒前
41秒前
CHERIE完成签到,获得积分10
43秒前
45秒前
在水一方应助耳东陈采纳,获得10
48秒前
善学以致用应助英勇羿采纳,获得10
49秒前
居居发布了新的文献求助10
51秒前
51秒前
风一样的风干肠完成签到 ,获得积分10
53秒前
T1aNer299发布了新的文献求助10
58秒前
59秒前
1分钟前
哈基米德应助科研通管家采纳,获得20
1分钟前
1分钟前
哈基米德应助科研通管家采纳,获得20
1分钟前
科研通AI2S应助科研通管家采纳,获得10
1分钟前
浮游应助科研通管家采纳,获得10
1分钟前
斯文败类应助科研通管家采纳,获得10
1分钟前
Jasper应助科研通管家采纳,获得10
1分钟前
哈基米德应助科研通管家采纳,获得20
1分钟前
Lucas应助科研通管家采纳,获得10
1分钟前
高分求助中
Encyclopedia of Quaternary Science Third edition 2025 12000
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
HIGH DYNAMIC RANGE CMOS IMAGE SENSORS FOR LOW LIGHT APPLICATIONS 1500
Holistic Discourse Analysis 600
Constitutional and Administrative Law 600
Vertebrate Palaeontology, 5th Edition 530
Fiction e non fiction: storia, teorie e forme 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 物理化学 基因 遗传学 催化作用 冶金 量子力学 光电子学
热门帖子
关注 科研通微信公众号,转发送积分 5345529
求助须知:如何正确求助?哪些是违规求助? 4480441
关于积分的说明 13946306
捐赠科研通 4377975
什么是DOI,文献DOI怎么找? 2405510
邀请新用户注册赠送积分活动 1398115
关于科研通互助平台的介绍 1370519